PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, April 28, 2016

PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research



open access

 Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-repair pathways.

.....Phase III trials are currently ongoing to further evaluate the role of PARP inhibitors in patients with EOC with mutated BRCA1-2 or high-grade serous or endometrioid histological type after platinum-based chemotherapy (Table III).
Germline BRCA1-2 testing should be offered to all women with non-mucinous EOC, regardless of age and family history (44, 95). However, HR deficiency has been observed not only in germline BRCA1-2 mutation carriers, but also in patients with EOC with somatic mutations of BRCA1 or BRCA2, epigenetic silencing of BRCA1, and loss of function of other genes (40, 41). Approximately half of all high-grade EOCs are HR-deficient, and therefore additional biological and clinical investigations are strongly warranted to identify this subset of tumors (46, 47, 96). Once HR deficiency becomes amenable to routine testing, a larger group of patients with EOC than those with mutated BRCA1-2 will benefit from the use of PARP inhibitors (97).
.

0 comments :

Post a Comment

Your comments?